-
Leerink Partners Starts Senti Biosciences, Inc. (SNTI) at Outperform
-
Senti Biosciences (SNTI) Misses Q3 EPS by 69c
-
H.C. Wainwright Starts Senti Biosciences, Inc. (SNTI) at Buy
-
Senti Biosciences (SNTI) Misses Q2 EPS by 56c
-
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
-
Senti Biosciences (SNTI) Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
-
Laidlaw Starts Senti Biosciences, Inc. (SNTI) at Buy
-
Senti Biosciences (SNTI) Releases Mechanism of Action Video for SENTI-202
-
Senti Biosciences (SNTI) Misses Q1 EPS by 141c
-
Senti Biosciences' (SNTI) SENTI-202 Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
-
Senti Biosciences (SNTI) Appoints James B. Trager to its Scientific Advisory Board
-
Senti Biosciences (SNTI) Joins Webull Corporate Connect Service Platform
-
Senti Biosciences (SNTI) Files $300M Mixed Shelf
-
Senti Biosciences (SNTI) Misses Q4 EPS by 67c
-
Senti Biosciences (SNTI) appoints Feng Hsiung to Board
-
Senti Biosciences (SNTI) Strengthens Leadership Team with Strategic Hires
-
Senti Biosciences (SNTI) Announces Additional $11.5M of Financing
-
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
-
Senti Biosciences (SNTI) Halted on Volatility, Now Up 493%
-
Senti Biosciences (SNTI) Announces Oversubscribed $37.6 Million Private Placement Equity Financing
-
Senti Biosciences (SNTI) Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202
-
Senti Biosciences (SNTI) Appoints Fran Schulz to its Board
-
Senti Biosciences (SNTI) Announces 1-for-10 Reverse Stock Split
-
Senti Biosciences (SNTI) Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy

